Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 28, 2016; 22(44): 9661-9673
Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9661
Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9661
Table 3 Summary of studies concerning cryosurgery
Authors | Number of patients | Lesion | Location | Treatment type | Approach | Needle | Mean treatment duration | Conclusion |
Xu et al[9] | 49 | Pancreatic ductal adenocarcinoma | - | Cryosurgery | 36 percutaneous with US or CT + 13 intraoperative | 2 or 3 mm | - | Cryosurgery is associated with a low rate of adverse effects |
Li et al[54] | 2 | Neuroendocrine tumors | Head and tail | Cryosurgery | Percutaneous with US and CT | 1.7 mm and 2 mm | 10 and 15 min | Percutaneous cryosurgery is minimally invasive and |
has advantages compared with conventional surgery | ||||||||
Niu et al[55] | 67 | Pancreatic ductal adenocarcinoma | - | Cryosurgery | Percutaneous with US and CT | 1.7 mm | - | Cryoimmunotherapy significantly increased overall survival in metastatic |
pancreatic cancer |
- Citation: D’Onofrio M, Ciaravino V, De Robertis R, Barbi E, Salvia R, Girelli R, Paiella S, Gasparini C, Cardobi N, Bassi C. Percutaneous ablation of pancreatic cancer. World J Gastroenterol 2016; 22(44): 9661-9673
- URL: https://www.wjgnet.com/1007-9327/full/v22/i44/9661.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i44.9661